< Zurück zu den aktuellen Neuigkeiten & Events

Wissens Hub

Preparing for change: The UPC opt-out decision

April 2016

The patent landscape in Europe is on the brink of the most significant change in a generation. This will affect all owners of European patents (EPs) who will need to make important decisions about their portfolios by the end of 2016.

Even if the UK votes to leave the EU, Unitary Patents (UPs) and the Unified Patent Court (UPC) are highly likely to come into effect and patentees will still need to make decisions about their granted EPs and applications.

We expect that by Q1/Q2 2017 patentees will be able to opt for a UP, a single patent covering up to 26 participating member states’ of the EU. In addition we will see the opening of the UPC, a central court that will transform patent litigation in the EU. It is vital to prepare your existing patent portfolio for the new patent landscape and there may be as little as 6 months’ notice of the UPC going live.

This is the first of a series of briefing notes where the UPC group at HGF will consider the key decisions patentees and applicants will need to make in order to navigate the new regime and make the best choices for their patent portfolios. In this note we focus on the decision that all owners and applicants of EPs will have to make: whether to opt their patents out of the jurisdiction of the UPC.

The opt-out

When the UPC opens for business, unless they are opted-out, granted EPs will be subject to the jurisdiction of the UPC as well as the relevant national courts. This will mean that you will be able to enforce your EPs in a single action across all Member States that have ratified the UPC and for which your patent is validated.

It will also mean that an EP can be revoked in a single action brought before the UPC’s Central Division. This is in contrast to the current position where an EP is a bundle of national rights, each of which must be revoked in separate actions in the national courts. Because this is such a fundamental change to European patent litigation, for a transitional period of at least 7 years, you will be able to exercise an opt-out to take existing, pending and future EPs out of the jurisdiction of UPC for the lifetime of those patents. The opt-out allows patentees to maintain the current position, i.e., any litigation must be before the relevant national court. The Rules of Procedure allow for a “sunrise” period before the UPC system goes live, in order for patentees to opt-out their existing EPs from the UPC’s jurisdiction before the court opens its doors.

Should I opt out?

Whether you should opt out your granted and pending EPs from the jurisdiction of the UPC will depend on many factors; there is no one size fits all. Patentees shouldn’t assume that opting out will be the best option: there may be advantages to keeping at least some of your patents within the jurisdiction of the UPC. As details of the Rules and Procedures for the UPC system have crystallised, many patentees are considering a nuanced approach to managing the opt-out (or remaining subject to the UPC’s jurisdiction) for their patent portfolio.

Considerations for remaining subject to the UPC’s jurisdiction (i.e. not opting out)
  • You may be able to obtain a pan-EU injunction throughout the participating Member States in a single infringement action before the
  • The target timeline for resolution of first instance proceedings within the UPC is 12 months, which while equivalent to proceedings before the English, Dutch and German Courts is significantly better than proceedings before many other national
  • After a transitional period of 7 years (likely to be extended to 14 years), you won’t be able to opt-out new Why not gain experience of the new system first hand and influence its development?
  • You may not have a choice. If you in-license a patent you may not have control over whether to opt-out that patent.

[1] In the beginning, it is anticipated that not all of the 26 Member States who have signed the UPC Agreement will have ratified the Agreement so validations of EPs in those countries will be treated in the same way as they are under the current system.

Considerations for exercising the opt-out
  • A single action before the UPC’s Central Division could lead to the revocation of the Therefore, a patentee might want to opt-out the “crown jewels” of their patent portfolio. This would mean that a patent would have to be revoked in the national courts across all validated member states.
  • If EPs are opted-out, only the national courts have jurisdiction; you maintain the status
  • In the beginning, the UPC will be an unknown and untested forum. One concern we hear consistently from patentees about the UPC, is about the quality and consistency of the judgments across all Local, Regional and Central
  • There is no fee for opting-out your patents but there are likely to be administration costs in terms of considering strategy and ensuring that the opt-out is validly implemented across a
  • Provided that there is no ongoing national litigation, you can withdraw an opt-out if you want to take advantage of the UPC at a future date (although a subsequent second opt-out will not be possible).
What steps should I take now?

If you have not already done so, you need to start considering your strategy as to whether you want to opt-out your EPs from the jurisdiction of the UPC.

Your review should consider the following issues:

  • the strength of the relevant patents;
  • the value of the technology covered by each patent or patent family to the business in the relevant jurisdiction;
  • how your various patents interact to protect your commercial products;
  • the likelihood in your industry that a third party will attack the validity of your patents;
  • for patents that are jointly owned or licensed into or out of the business — who has the right to exercise the opt-out of the EPs (and any associated SPC)?

This exercise needs to be done sufficiently ahead of the launch of the UPC in order to give you time to execute any opt-out during the sunrise period.

If you decide to exercise the opt-out, it is important to ensure that the correct party or parties exercise that opt-out to ensure that it is validly executed. If you fail to validly opt-out, then there is a risk that competitors might seek to revoke the patent centrally at the UPC.

If you would like to discuss strategy development or portfolio review, HGF can provide you with assistance and guidance on formulating and implementing your company’s plan for the UPC. Should you have any further questions about the UPC and opt-out please contact our dedicated UPC team on upcready@hgf.com or contact your usual attorney to discuss these issues further.

Download our Briefing Notes for more information

Aktuelle Neuigkeiten

Event - 24. Juni 2026

IP Clinic for SMEs at ETZ EnergyWorks

Following the success of our first session, we’re pleased to announce our next Intellectual Property (IP) clinic taking place at ETZ EnergyWorks in Aberdeen on Wednesday 24 June 2026, from …

Veranstaltungsdetails
Event - 2. Juni 2026

HGF ist stolzer Sponsor der Retail Week General Counsel 2026

HGF ist stolz darauf, die Retail Week General Counsel zu sponsern. Die Veranstaltung findet am Mittwoch, den 3. Juni, im Ham Yard Hotel statt. Die rechtliche Landschaft im Einzelhandel befindet …

Veranstaltungsdetails
Event - 5. Mai 2026

IP‑Klinik für KMU bei ETZ EnergyWorks

Wir freuen uns, eine kostenlose Klinik für geistiges Eigentum (IP) ankündigen zu können, die am Mittwoch, den 27. Mai, von 11:00 bis 16:00 Uhr bei ETZ EnergyWorks in Aberdeen stattfindet …

Veranstaltungsdetails
Event - 11. bis 12. Mai 2026

HGF ist stolz darauf, am 14th Microbiome R&D and Business Collaboration Forum: Europe sowie am 8th Skin Microbiome and Cosmeceuticals Congress: Europe teilzunehmen.

HGF ist stolz darauf, am 14th Microbiome R&D and Business Collaboration Forum: Europe sowie am 8th Skin Microbiome and Cosmeceuticals Congress: Europe teilzunehmen. Die Veranstaltung findet am Montag, den 11., …

Veranstaltungsdetails
Event - 27. April 2026

HGF ist stolz darauf, Gold Sponsor des IP Counsel Café zu sein

HGF ist stolz darauf, Gold Sponsor des IP Counsel Café zu sein, das vom 12. bis 14. Mai im Silicon Valley, USA, stattfindet. Die HGF‑Partnerin Susan Keston wird zum Thema …

Veranstaltungsdetails
Event - 16. April 2026

MedTech Innovation Summit 2026

Adam Hines, Partner bei HGF und Patentanwalt, wird am MedTech Innovation Summit Dublin 2026 teilnehmen, der vom 28. bis 30. April im The Shelbourne Hotel stattfindet. Als eine der führenden …

Veranstaltungsdetails
Event - 2. bis 6. Mai 2026

INTA-Jahrestagung 2026

Das europäische Team von HGF freut sich, an der INTA-Jahrestagung 2026 teilzunehmen, die vom 2. bis 6. Mai in London stattfindet. Als eine der führenden IP-Kanzleien Europas vereint HGF Anwältinnen …

Veranstaltungsdetails
Event - 25. März 2026

HGF‑Event: Women IP Inclusive

Dieses Jahr organisiert HGF in Partnerschaft mit dem CIPA das Networking‑Event Connected Bubbles – am Mittwoch, den 25. März 2026! In einem Berufsfeld, das auf Zusammenarbeit, Empfehlungen und Vertrauen basiert, …

Veranstaltungsdetails